In this context, we have explored the PSGL-1 pathway activation in OSA patients without clinical evidence of cancer, exploring its contribution to the disruption of immune surveillance prior to tumor initiation. This evidence concerns the gene SELPLG and obstructive sleep apnea syndrome.